Stay in the know
Receive timely insights and briefings from HSF Kramer, tailored to keep you informed and ahead
Subscribe now
Herbert Smith Freehills Kramer (HSF Kramer) is pleased to be advising CSL on its recently announced proposed demerger of its Seqirus business (Seqirus) as a standalone ASX-listed entity by the end of Financial Year 2026.
Seqirus is one of the world’s largest influenza vaccine providers, dedicated to advancing public health through innovative vaccine solutions and pandemic preparedness.
The HSF Kramer team is led by partners Priscilla Bryans, Baden Furphy, Alexander Mackinnon, and Michael Ziegelaar, with partner Ryan Leslie advising on the tax aspects of the transaction.
Key contacts
Priscilla Bryans
Partner, Melbourne
Baden Furphy
Partner, Melbourne
Alexander Mackinnon
Partner, Melbourne
Michael Ziegelaar
Partner, Melbourne
Ryan Leslie
Partner, Melbourne
Media contact
For further information on this news article, please contact:
Gina Baldassarre
External Communications Manager
Sydney
More news
30 outubro 2026
Herbert Smith Freehills Kramer supports inaugural AI and Social Mobility Challenge Prize
Leading global law firm Herbert Smith Freehills Kramer has supported the inaugural AI and Social Mobility Challenge Prize, an initiative exploring how AI …
29 outubro 2026
Asia Private Capital Q3 2026: Selective capital, rising exits and deflecting valuation disputes
Asia’s private capital market delivered a mixed third quarter. Deal activity rose 8% quarter on quarter, while fundraising remained under pressure and …
28 outubro 2026
Herbert Smith Freehills Kramer advises Zain on landmark telecom tower joint venture with Ooredoo
Leading global law firm Herbert Smith Freehills Kramer has advised Zain Group, a leading telecommunications provider operating across the Middle East and …